Drug Trial Radar · NCT07128121
A Phase 2 Study to Describe the Safety and Immunogenicity of Respiratory Syncytial Virus Vaccine IN006 in Healthy Participants Aged 60 Years and Older
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
500
Planned (sponsor's estimate)
Start
Aug 13, 2025
Primary completion
Oct 2029
Study completion Oct 2029
Sponsor
- Lead sponsor
- Shenzhen Shenxin Biotechnology Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Aug 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The study will evaluate the safety, tolerability, and immunogenicity of 2 dose levels of IN006 in healthy participants who aged at 60 years or older; of a revaccination of IN006 given 12 months or 24 months after the initial vaccination.
Conditions
- Respiratory Syncytial Virus (RSV) Infection
Interventions
Respiratory Syncytial Virus IN006 Bivalent mRNA Vaccine (IN006)Biological
Formulation for injection
PlaceboBiological
0.9% sodium chloride (normal saline) injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Solicited Local and Systemic Adverse Reactions Through 14 Days After Initial VaccinationTime frame: From initial vaccination up to14 days post initial vaccination
- Percentage of Participants With Unsolicited Adverse Events (AEs) Through 28 Days After Initial VaccinationTime frame: From initial vaccination up to 28 days post initial vaccination
- Percentage of Participants With Unsolicited AEs Through 30 Minutes After Initial VaccinationTime frame: From initial vaccination up to 30 minutes post initial vaccination
- Percentage of Participants With Any Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs) During StudyTime frame: Through study completion, about 3 years at most
- Percentage of Abnormal Results of Hematology On Day 3 After Initial Vaccination Compared with BaselineTime frame: From initial vaccination up to 3 days post initial vaccination
- Percentage of Abnormal Results of Clinical Chemistry On Day 3 After Initial Vaccination Compared with BaselineTime frame: From initial vaccination up to 3 days post initial vaccination
- Percentage of Abnormal Results of Coagulation On Day 3 After Initial Vaccination Compared with BaselineTime frame: From initial vaccination up to 3 days post initial vaccination
- Percentage of Participants With Any AEs Leading to Discontinuation of Vaccination or Withdrawal From The StudyTime frame: Through study completion, about 3 years at most
- Geometric mean concentration (GMC) for Pre-F Specific IgG Antibody Against RSV A and RSV BTime frame: 1 month post-initial vaccination
- Geometric Mean Fold Rise (GMFR) for Pre-F Specific IgG Antibody Against RSV A and RSV BTime frame: 1 month post-initial vaccination
- Seroconversion Rate (SCR) for Pre-F Specific IgG Antibody Against RSV A and RSV BTime frame: 1 month post-initial vaccination
- Geometric mean titer (GMT) for Neutralizing Antibody Against RSV A and RSV BTime frame: 1 month post-initial vaccination
- GMFR for Neutralizing Antibody Against RSV A and RSV BTime frame: 1 month post-initial vaccination
- SCR for Neutralizing Antibody Against RSV A and RSV BTime frame: 1 month post-initial vaccination
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hunan Provincial Center for Disease Control and Prevention
Changsha, Hunan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.